LABONACHIP, LLC

Labonachip, LLC

Company Overview

POINT OF CARE, MULTI ASSAY DIAGNOSTICS, WITHOUT THE LAB

The world's first in-vitro diagnostic platform, about the size of a postage stamp, for multi-step enzyme-linked immunoassays

Autonomous, fluid activated valve inside a cellulose paper test strip

Technology under exclusive license agreement from URI

Labonachip, LLC

Problem

Large, fully equipped labs are expensive for running tests and can take days to register results

Access to lab testing is not available to patients without an order from their physician

Labonachip, LLC

Solution

Lower testing cost vs full lab setup

Rapid diagnostics

Ease of usability for patients

OTC accessible – patients can use before seeing their physician

Labonachip, LLC

Team

Constantine Anagnostopoulos, Ph.D.,

President, Co-founder



Mohammed Faghri, Ph.D.,

Co-Founder and Scientific Advisor

To be hired

Operations Manager

To be hired

Sales Consultant

Labonachip, LLC

Advisory Board

Hong Chen, Ph.D.,
Technology Advisor

Athena Anagnostopoulos,
Design Advisor



MariaGrazia Ruocco,
Business Development Manager

Salma de la Feld, M.D.,
Medical Advisor

Sanaz Faghri, M.D.,
Clinical Advisor

Steven Powers, Ph.D.,
Diagnostics Industry Advisor

Edwin Datson, MBA,
Investor Relations Advisor

To be hired
Chemist

Labonachip, LLC

Target market: US Infectious Disease - Influenza

Screening test in the US for infectious diseases (i.e influenza)

Consumer OTC – will purchase it before seeing their doctor

Lower bar to break into the market with low cost of development

Relatively low regulations for screening test vs. diagnostic test on which a course of treatment will be based

Labonachip, LLC

Product Vision/Core Technology



Labonachip, LLC

Competition

CHEMBIO
DIAGNOSTIC SYSTEMS

ID NOW™

CORIS
BIO CONCEPT

Labonachip, LLC

Regulatory

Clinical Laboratory Improvement Amendments (CLIA)

Regulates all facilities in the US that perform laboratory testing on human specimens for health assessment or the diagnosis, prevention, or treatment of disease

CLIA waived tests are cleared by the FDA for home use

Waived tests must be simple and have a low risk for erroneous results

This does not mean that waived tests are completely error-proof.

Labonachip, LLC

Intellectual Property

US 8945485

US 9415393

US 9687846



Primary patent filed in 2014

Patent pertains to a simple and inexpensive method of creating a multi-channel ELSA

Patent has over 15 years of protection based on filing date

Project Timetable



Labonachip, LLC

Financial Projection

COGS	Sales Price		Volume	Top Line	20% EBITDA	Value
$4	$8	x	1,000,000	$8M	$2M	$20M



Labonachip, LLC

Exit Plan

Move to rapid diagnostic means there are many potential acquirers such as Tamiflu, Johnson & Johnson, or CVS/Aetna for complimentary testing

Johnson & Johnson FAMILY OF COMPANIES

Tamiflu™ oseltamivir phosphate

CVS Health | aetna